AstraZeneca weighs seeking full US approval for COVID-19 shot

AstraZeneca Plc may skip asking the US Food and Drug Administration for emergency-use authorization for its COVID-19 vaccine, and instead pursue the more time-intensive application for a full-fledged license to sell the shot, the Wall Street Journal reported on Friday.
Such a step would further delay any rollout of the British drugmaker's shots in the United States, according to the report, which cited people familiar with the matter.
Subscribe for our daily newsletter
Subscribe for our daily newsletter

By subscribing I accept the terms of use and privacy policy

Read all Tweets >